Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition

Resistance to the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib has been attributed solely to mutations in BTK and related pathway molecules. Using whole-exome and deep-targeted sequencing, we dissect evolution of ibrutinib resistance in serial samples from five chronic lymphocytic leukaem...

Descripción completa

Detalles Bibliográficos
Autores principales: Burger, Jan A., Landau, Dan A., Taylor-Weiner, Amaro, Bozic, Ivana, Zhang, Huidan, Sarosiek, Kristopher, Wang, Lili, Stewart, Chip, Fan, Jean, Hoellenriegel, Julia, Sivina, Mariela, Dubuc, Adrian M., Fraser, Cameron, Han, Yulong, Li, Shuqiang, Livak, Kenneth J., Zou, Lihua, Wan, Youzhong, Konoplev, Sergej, Sougnez, Carrie, Brown, Jennifer R., Abruzzo, Lynne V., Carter, Scott L., Keating, Michael J., Davids, Matthew S., Wierda, William G., Cibulskis, Kristian, Zenz, Thorsten, Werner, Lillian, Cin, Paola Dal, Kharchencko, Peter, Neuberg, Donna, Kantarjian, Hagop, Lander, Eric, Gabriel, Stacey, O'Brien, Susan, Letai, Anthony, Weitz, David A., Nowak, Martin A., Getz, Gad, Wu, Catherine J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4876453/
https://www.ncbi.nlm.nih.gov/pubmed/27199251
http://dx.doi.org/10.1038/ncomms11589

Ejemplares similares

Ejemplares similares